| "Sanofi Aventis"(SNY)
|"Sanofi-Aventis" Graph source Edgar Online Pro on April 21st, 2006
The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 20-F For the Year Ended December 31, 2005 . The overview of the company was:
Sanofi-Aventis, through its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceutical products and human vaccines worldwide. It offers various pharmaceutical products for various therapeutic areas, including cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, and internal medicine. The company’s product portfolio includes Aprovel and Tritace, two hypertension treatment products for cardiovascular diseases; metabolic disorders products, which includes Lantus, a long acting analogue insulin and Amaryl, a once-daily sulfonylurea; oncology drugs that comprise Taxotere, a taxane derivative representing a cornerstone therapy in various cancer types, and Eloxatine, an platinum agent for metastatic colorectal cancer; and central nervous system medicines, which include Stilnox for insomnia, Copaxone for multiple sclerosis, and Depakine for epilepsy treatments. Sanofi-Aventis also offers thrombosis products comprising Plavix, an anti-platelet agent indicated for atherothrombotic conditions, and Lovenox, a low molecular weight heparin for deep vein thrombosis and for unstable angina and non-Q-wave myocardial infarction; and internal medicine products that include Allegra for respiratory/allergy, Nasacort for allergic rhinitis, Xatral for prostatic hypertrophy, and Actonel for osteoporosis. Its human vaccines include pediatric combination vaccines, influenza vaccines, polio vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel vaccines. The company was founded in 1970 and is headquartered in Paris, France.
Our business includes two main activities: pharmaceuticals (principally prescription drugs) and human vaccines.
In our pharmaceuticals activity, which generated net sales of €25,249 million in 2005, we specialize in six therapeutic areas:
• Cardiovascular: Our cardiovascular products include two major hypertension treatments: Aprovel ® and Tritace ® .
• Thrombosis: Our thrombosis products include two leading drugs in their categories: Plavix ® , an anti-platelet agent indicated for a number of atherothrombotic conditions, and Lovenox ® , a low molecular weight heparin indicated for deep vein thrombosis and for unstable angina and non-Q-wave myocardial infarction.
• Metabolic Disorders: Our products for metabolic disorders include Lantus ® , a long acting analog which is a leading brand in the insulin market, and Amaryl ® , a once-daily sulfonylurea.
• Oncology: Our lead products in the strategic oncology market are Taxotere ® , a taxane derivative representing a cornerstone therapy in several cancer types, and Eloxatine ® , an innovative platinum agent, which is a leading treatment of metastatic colorectal cancer.
• Central Nervous System (CNS): Our CNS medicines include Stilnox ® /Ambien CR™, the world’s leading insomnia prescription medication; Copaxone ® , an immunomodulating agent indicated in multiple sclerosis; and Depakine ® , a leading epilepsy treatment.
• Internal Medicine: In internal medicine, we are present in several fields. In respiratory/allergy, our products include Allegra ® , a non-sedating prescription antihistamine, and Nasacort ® , a local corticosteroid indicated in allergic rhinitis. In urology, we are present with Xatral ® , a leading treatment for benign prostatic hypertrophy. In osteoporosis, we are present with Actonel ® .
Our top fifteen products are Lovenox ® , Plavix ® , Taxotere ® , Eloxatine ® , Stilnox ® , Allegra ® , Lantus ® , Tritace ® , Copaxone ® , Aprovel ® , Amaryl ® , Actonel ® , Depakine ® , Xatral ® and Nasacort ® , which together accounted for 64.1% of our net sales for the pharmaceutical activity, or €16,188 million, in 2005.
In the human vaccines activity, we are a major player with leading vaccines in five areas:
• Pediatric combination vaccines providing protection against such diseases as pertussis, diphtheria, tetanus, and Haemophilus influenza type b. Our main products are Daptacel ® , Tripedia ® , Act-HIB ® , Pentacel ™ , Pediacel ® and Tetract-Hib ® . We also produce polio vaccines, such as Ipol ® and Imovax ® Polio, as well as oral polio formulations, all of which contribute to polio eradication strategies in both developed and developing countries.
• Influenza vaccines, which experienced strong growth in the Northern Hemisphere with Fluzone ® and Vaxigrip ® .
• Adult and adolescent booster vaccines protecting against pertussis, tetanus, diphtheria and polio (in several products). Our main products include: Adacel ® (the first trivalent booster against pertussis, tetanus and diphtheria for adolescents and adults), Decavac ® , Repevax ® and Revaxis ® .
• Meningitis vaccines, where our main products are the quadrivalent vaccines Menactra ® and Menomune ® . Menactra ® (approved by the FDA in January 2005) is a conjugate vaccine that is expected to provide a longer-lasting immune response.
• Travel/Endemic vaccines, which include a wide range of vaccines against hepatitis A, typhoid, rabies, yellow fever, Japanese encephalitis, cholera, Enterotoxigenic Escherichia coli (ETEC) and anti-venoms. Key products include Imovax ® Rabies, Verorab ® , Typhim Vi ® , Avaxim ® and Vivaxim ® .
In 2005, the human vaccines business recorded net sales of €2,062 million, significantly boosted by three successful launches in the United States (Decavac ® in January, Menactra ® in March and Adacel ® in July) and a highly successful influenza vaccination season.
We have a strong commitment to research and development. We have 28 research centers and over 17,600 employees (including Vaccines, Industrial Development and Medical/Regulatory staff in subsidiaries) devoted to research and development.
Highlights of Risks Related to Our (SNY) Business
For further detail please review the 20 F Form in detail.
A. Risks Relating to Our (SNY)Company
1. The integration of the new Group’s activities presents significant challenges that may result in the combined business not operating as effectively as expected or in the failure to achieve some or all of the anticipated benefits of the business combination.
2. We incurred substantial debt in connection with the acquisition of Aventis, which limits our business flexibility and requires us to devote cash resources to debt service payments.
3. We depend on the United States market for a significant part of our current and future operating results. A failure to continue our strategy of profitable operations in that market could adversely affect our business, results of operations, financial condition or prospects.
4. We depend on third parties for the marketing of some of our products. These third parties may act in ways that could harm our business.
5. The manufacture of our products is technically complex, and supply interruptions, product recalls or inventory losses caused by unforeseen events may reduce sales, delay the launch of new products and adversely affect our operating results and financial condition.
6. We depend on third parties for the manufacture and supply of a substantial portion of our raw materials, specialized components, active ingredients and medical devices.
7. Our collaborations with third parties expose us to risks that they will assert intellectual property rights on our inventions or fail to keep our unpatented technology confidential.
8. Claims relating to marketing practices could adversely affect our business, results of operations and financial condition.
9. Fluctuations in currency exchange rates could adversely affect our results of operations and financial condition.
B. Risks Relating to Our (SNY) Industry
1. We must invest substantial sums in research and development in order to remain competitive, and we may not fully recover these investments if our products are unsuccessful in clinical trials or fail to receive regulatory approval.
2. The research and development process is lengthy and carries a substantial risk of product failure. If our research and development does not yield sufficient new products that achieve commercial success, our future operating results may be adversely affected.
3. If we are unable to protect our proprietary rights, we may fail to compete effectively or operate profitably.
4. Product liability claims could adversely affect our business, results of operations and financial condition.
5. Use of biologically derived ingredients may face consumer resistance, which could adversely affect sales and cause us to incur substantial costs.
6. We face uncertainties over the pricing of pharmaceutical products.
7. Changes in the marketing status or competitive environment of our major products could adversely affect our results of operations.
8. Risks from the handling of hazardous materials could adversely affect our results of operations.
9. Environmental liabilities and compliance costs may have a significant adverse effect on our results of operations.
10. Risks Relating to an Investment in our Shares or ADSs
11. Foreign exchange fluctuations may adversely affect the U.S. dollar value of our ADSs and dividends (if any).
12. If you hold ADSs rather than shares it may be difficult for you to exercise some of your rights as a shareholder.
13. Our two largest shareholders own a significant percentage of the share capital and voting rights of sanofi-aventis.
14. Sales of our shares may cause the market price of our shares or ADSs to decline.
Recent articles on the medical industry:
For New Research Projects Contact The Chairman at Email: email@example.com
Disclaimer of Warranty and Limitation of Liability
products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.
The KIN Consortium does not warrant the information or services provided herein or your use of this
web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties,
including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose.
The KIN Consortium will not be responsible for any loss or damage that could result from interception
by third parties of any information or services made available to you via this web site. Although the information provided
to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium
cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available
to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors,
officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage
that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any
other party involved in making this web site, the data contained herein or the products or services offered on this web site
available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these
materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN
Consortium or of any vendor providing software or services. In no event will The KIN Consortium
or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental
damages or any other damages of any kind even if The KIN Consortium or any other such party has been
advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any
viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone
or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator
errors, strikes or other labor problems. The KIN Consortium cannot and does not guarantee continuous,
uninterrupted or secure access to the web site.
All right, title and interest
in this web site and any content contained herein is the exclusive property of The KIN Consortium ,
except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and
you may print, copy and download any information or portion of this web site for your personal use only. You may not modify,
copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer,
or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products
or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior
written approval. If you copy or download any information or software from this web site, you agree that you will not remove
or obscure any copyright or other notices or legends contained in any such information.
The KIN Consortium and
other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium .
The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks
of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags
on other pages or sites on the World Wide Web without the written permission of The KIN Consortium
or such third party, which may own the marks.
Pursuant to Section 512(c)(2) of the Copyright Act, The KIN
Consortium designates the following agent to receive notifications of claimed infringement: Khalid I Natto,
The KIN Consortium , Email: firstname.lastname@example.org, Website: http://khalidnatto.tripod.com
Use of Links
This web site contains links
to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply
an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium
of any information contained in any third party web site. In no event shall The KIN Consortium be responsible
for the information contained on that site or your use of or inability to use such site. You should also be aware that the